ImmunoGen, Inc. (NASDAQ:IMGN) VP Anna Berkenblit sold 5,851 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $9.46, for a total value of $55,350.46. Following the sale, the vice president now directly owns 138,620 shares of the company’s stock, valued at approximately $1,311,345.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
IMGN opened at $9.26 on Friday. ImmunoGen, Inc. has a 1-year low of $4.80 and a 1-year high of $13.41. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.76 and a quick ratio of 5.73. The company has a market capitalization of $1.39 billion, a PE ratio of -12.35 and a beta of 1.95.
ImmunoGen (NASDAQ:IMGN) last posted its quarterly earnings data on Friday, July 27th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02). The firm had revenue of $9.29 million during the quarter, compared to the consensus estimate of $14.12 million. The company’s revenue for the quarter was down 76.2% compared to the same quarter last year. During the same period last year, the company earned ($0.10) earnings per share. sell-side analysts predict that ImmunoGen, Inc. will post -1.19 EPS for the current year.
IMGN has been the subject of several research reports. ValuEngine cut ImmunoGen from a “strong-buy” rating to a “buy” rating in a research report on Thursday, June 28th. BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a research report on Thursday, June 21st. HC Wainwright set a $18.00 price objective on ImmunoGen and gave the company a “buy” rating in a research report on Wednesday, June 13th. Finally, Cowen reissued a “hold” rating on shares of ImmunoGen in a research report on Thursday, May 17th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $12.42.
Hedge funds and other institutional investors have recently modified their holdings of the stock. SG Americas Securities LLC acquired a new position in shares of ImmunoGen in the second quarter valued at $115,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of ImmunoGen by 198.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,144 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 7,411 shares in the last quarter. Quantitative Systematic Strategies LLC acquired a new position in shares of ImmunoGen in the first quarter valued at $126,000. Private Advisor Group LLC acquired a new position in shares of ImmunoGen in the second quarter valued at $131,000. Finally, Great West Life Assurance Co. Can raised its stake in shares of ImmunoGen by 75.1% in the second quarter. Great West Life Assurance Co. Can now owns 15,767 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 6,763 shares in the last quarter. Institutional investors and hedge funds own 83.77% of the company’s stock.
ImmunoGen, Inc, a clinical-stage biotechnology company, focuses on developing antibody-drug conjugate (ADC) therapies to treat cancer. Its product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha, which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; IMGN779 that is in Phase I clinical trial for the treatment of acute myeloid leukemia (AML); and IMGN632, a CD123-targeting ADC that is in Phase I clinical trial for treating AML and blastic plasmacytoid dendritic cell neoplasm, as well as coltuximab ravtansine, a CD19-targeting ADC, which is in Phase II trial for DLBCL.
Featured Article: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.